{"prompt": "['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', '5.11.3.5', 'Investigator responsibilities relating to safety reporting', 'The Investigator will assume overall responsibility for evaluating and reporting adverse events. In', 'urgent situations, a member of the trial team may report on their behalf, while making every effort to', 'discuss the event with them. The investigator may consult the study medical monitor for advice, but', 'they will assume overall responsibility for the evaluation, assignment of clinical significance and', 'reporting of adverse events. All non-serious AEs and ARs, whether expected or not, should be', \"recorded in the participant's medical notes, including all events observed following ATIMP\", 'administration, and in the eCRF. These should be entered on to the database according to the', 'timelines defined in the CNGA3 Gene Therapy trial for Achromatopsia Data Management Plan to allow', 'appropriate monitoring by the CMT. SAEs and SARs should be notified to PV Service Provider', 'immediately the investigator becomes aware of the event (in no circumstance should this notification', 'take longer than 24 hours).', 'Clinically significant abnormalities in the results of objective tests will also be recorded as adverse', 'events. If the results are not expected as part of disease or surgery these will also be recorded as', 'unexpected. There are currently no expected events associated with the ATIMP.', 'All serious adverse events will be recorded in the hospital notes and the eCRF. Adverse events will be', 'recorded with clinical symptoms and accompanied with a simple, brief description of the event,', 'including dates as appropriate. All adverse events will be recorded until the end of the trial (refer to', 'Section 5.6.3 for definition), or until pregnancy outcome in the case of pregnancy. All SAEs will be', 'recorded, fully investigated and appropriately managed until resolution or stabilisation and CI sign off.', '5.11.3.5.1', 'Seriousness assessment', 'When an AE or AR occurs, the investigator responsible for the care of the participant must first assess', 'whether or not the event is serious using the definition given in Table 3. If the event is classified as', \"'serious' an SAE form must be completed and emailed to PV Service Provider (or delegated body)\", 'notified within 24 hours of the investigator becoming aware of the event.', '5.11.3.5.2', 'Severity or grading of Adverse Events', 'The severity of all AEs and/or ARs (serious and non-serious) in this trial should be graded using the', 'toxicity grading in NIH CTCAE Version 5.0 (NIH, 2018).', 'Table 4: Grading of Adverse Events', 'Category', 'Definition', 'Mild (Grade I)', 'Asymptomatic or mild symptoms; clinical or diagnostic', 'observations only; intervention not indicated', 'Moderate (Grade II)', 'Minimal, local or non-invasive intervention indicated; limiting', 'age appropriate instrumental ADL*', 'Severe (Grade III)', 'Severe or medically significant but not immediately life', 'threatening; hospitalisation or prolongation of hospitalisation', 'indicated; disabling; limiting self-care ADL**', 'Grade IV', 'Life threatening consequences; urgent intervention indicated', 'Grade V', 'Death related to AE', '* Instrumental ADL (Activities of Daily Living) refer to preparing meals, shopping for groceries or', 'clothes, using the telephone, managing money, etc', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 53 of 68']['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', '**Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking', 'medications, and not bedridden.', '5.11.3.5.3', 'Causality', 'Causality will be assessed in terms of both the ATIMP and the surgical procedures. Based on all', 'available information at the time of completion of the case report form, the investigator must assess', 'the causality of all serious events or reactions. It is of importance in this trial to capture and', 'differentiate events related to:', 'The ATIMP administration surgery', 'The ATIMP', 'The differentiated causality assessments will be captured in the trial specific CRF and SAE form. If the', 'event is related to the ATIMP, definitions in Table 5 will be used to capture the information. Any event', 'that is only related to the ATIMP administration surgery will be classified as an Adverse Event. The', 'study medical monitor is available 24/7 to provide any advice as required', 'Table 5: Causality definitions', 'Relationship', 'Description', 'Event Type', 'Unrelated', 'There is no evidence of any causal relationship', 'Unrelated SAE', 'Unlikely to be related', 'There is little evidence to suggest that there is a causal', 'Unrelated SAE', 'relationship (e.g., the event did not occur within a reasonable', 'time after administration of the trial medication). There is', 'another reasonable explanation for the event (e.g., the', \"participant's clinical condition or other concomitant treatment)\", 'Possibly related', 'There is some evidence to suggest a causal relationship (e.g.,', 'SAR', 'because the event occurs within a reasonable time after', 'administration of the trial medication). However, the influence', 'of other factors may have contributed to the event (e.g., the', \"participant's clinical condition or other concomitant treatment)\", 'Probably related', 'There is evidence to suggest a causal relationship and the', 'SAR', 'influence of other factors is unlikely', 'Definitely related', 'There is clear evidence to suggest a causal relationship and other', 'SAR', 'possible contributing factors can be ruled out.', '5.11.3.5.4', 'Expectedness', 'In view of the very limited clinical experience with the ATIMP there are at present no events', 'considered as expected for the ATIMP. Therefore, any SAEs that are related to the ATIMP (i.e.,', 'considered a SAR) will be deemed a SUSAR (suspected, unexpected, serious adverse reaction) and', 'MHRA, REC/IBC, FDA, and NIH reporting guidelines apply (see Notifications sections of the protocol).', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 54 of 68']\n\n###\n\n", "completion": "END"}